Trendlines Group

Founded 1993
Founders Steve Rhodes Todd Dollinger

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 43
Average round size
info
The average size of a deal this fund participated in
$2M
Portfolio companies 39
Rounds per year 1.54
Lead investments 9
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.14
Exits 9
Key employees 3
Stages of investment
Early Stage Venture
Late Stage Venture
Seed

Areas of investment

  • Biotechnology
  • AgTech
  • Health Care
  • Medical Device
  • Agriculture
Summary

In 1993 was created Trendlines Group, which is appeared as VC. The company was established in Asia in Israel. The leading representative office of defined VC is situated in the Misgav.

The usual cause for the fund is to invest in rounds with 2-3 partakers. Despite the Trendlines Group, startups are often financed by OurCrowd, EASME - EU Executive Agency for SMEs, The We Company. The meaningful sponsors for the fund in investment in the same round are Gefen Capital, Startup-O, Sirius Venture Capital Pte Ltd. In the next rounds fund is usually obtained by The Zitelman Group, Sirius Venture Capital Pte Ltd, Pitango Venture Capital.

Among the most popular portfolio startups of the fund, we may highlight LifeBond Ltd., The Agency for Science, Technology and Research, Nephera. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Israel. Among the most successful fund investment fields, there are Software, Food and Beverage.

The fund was created by Steve Rhodes, Todd Dollinger. Besides them, we counted 6 critical employees of this fund in our database.

The higher amount of exits for fund were in 2012. The high activity for fund was in 2016. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 1 percentage points less often commits exit comparing to other organizations. The fund is constantly included in less than 2 deals per year. This Trendlines Group works on 24 percentage points less the average amount of lead investments comparing to the other organizations. Deals in the range of 5 - 10 millions dollars are the general things for fund.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

AgroScout

Agriculture
AgTech
Information Technology
Machine Learning
$7M04 Aug 2021 Misgav Regional Council, North District, Israel

Equinom

Biotechnology
Clean Energy
Genetics
Organic Food
$20M22 Jun 2021 Rishon Lezion, Center District, Israel

IBI-Ag

Biotechnology
21 Jun 2021 Ness Ziona, HaMerkaz, Israel

ViAqua Therapeutics

Biotechnology
Health Care
Medical
Therapeutics
$4M09 Jun 2021 Misgav Regional Council, North District, Israel

PlanetWatchers

Analytics
Computer Vision
Geospatial
Machine Learning
Natural Resources
$3M03 Jun 2021 London, England, United Kingdom

ZygoFix

Medical Device
$2M09 Mar 2021 North District

Limaca Medical

$1M10 Nov 2020 North District

Phytolon

Biotechnology
Food and Beverage
Organic
$4M16 Sep 2020 Israel, North District, Israel

Vessi Medical

Medical Device
$1M31 Aug 2020 Israel, North District
News
Vensica Therapeutics Closes $16 Million Investment Round

– Vensica closed an investment round of $16m.
– The round was led by Israel Biotech Fund (“IBF”), a venture fund investing in Israeli and Israeli-related biotechnology and pharmaceutical companies.
– Other investors in the round include Laborie, a global urology device company, Lew Pell, an experienced medical device investor, Agriline, a trust of which Vincent Tchenguiz is a discretionary beneficiary, and The Trendlines Group, an investor in innovation-based medical and agricultural technologies.
– Funds raised will support the company’s phase II multicenter clinical trials in Europe and the USA.

ViAqua Therapeutics Announces $4.3 Million Investment led by S2G Ventures for its RNA-based Aquaculture Health Platform

– ViAqua Therapeutics, a biotechnology company and developer of an orally administered RNA-particle platform to promote and improve animal health in aquaculture, announced it has completed a $4.3m round to commercialize and expand its platform.
– Multinational new investors include: S2G Ventures (S2G Oceans & Seafood Fund), Thai Union, and Agriline.
– Earlier investors Nutreco, Visvires New Protein, The Trendlines Group (SGX:42:T;OTCQX: TRNLY) and the Technion Israel Institute of Technology also participated in this round.
– ViAqua was also awarded additional grant funding from the Israeli Innovation Authority.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Trendlines Group?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: